Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial

The Lancet Neurology

Volumn 16, Issue 4, 2017, Pages 301-310

  Amarenco, Pierre ^a   Albers, Gregory W ^b   Denison, Hans ^c   Easton, J Donald ^d   Evans, Scott R ^e   Held, Peter ^c   Hill, Michael D ^f   Jonasson, Jenny ^c   Kasner, Scott E ^g   Ladenvall, Per ^c   Minematsu, Kazuo ^h   Molina, Carlos A ⁱ   Wang, Yongjun ^j   Wong, K S Lawrence ^k   Johnston, S Claiborne ^l  

^a BICHAT HOSPITAL   (France)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c ASTRAZENECA R AND D   (Sweden)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f UNIVERSITY OF CALGARY   (Canada)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

ⁱ HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^j CAPITAL MEDICAL UNIVERSITY   (China)

^k CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^l UNIVERSITY OF TEXAS AT AUSTIN   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; TICAGRELOR; ADENOSINE; FIBRINOLYTIC AGENT;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BLEEDING; BRAIN ISCHEMIA; CAROTID ARTERY OBSTRUCTION; CAROTID ENDARTERECTOMY; CLINICAL OUTCOME; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; EXPLORATORY RESEARCH; FEMALE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TRANSIENT ISCHEMIC ATTACK; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMPLICATION; DOSE RESPONSE; INTERNATIONAL COOPERATION; ISCHEMIC ATTACK, TRANSIENT; MIDDLE AGED; MULTICENTER STUDY; PROPORTIONAL HAZARDS MODEL; STROKE; TREATMENT OUTCOME;

ADENOSINE; ADULT; AGED; ASPIRIN; ATHEROSCLEROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INTERNATIONAL COOPERATION; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; STROKE; TREATMENT OUTCOME;

EID: 85013679781     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(17)30038-8     Document Type: Article

References (25)

1. 1 Antithrombotic Trialists' (ATT) Collaboration, Baigent, C, Blackwell, L, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373 (2009), 1849–1860.
2. 2 Markus, HS, Droste, DW, Kaps, M, et al. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using Doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. Circulation 111 (2005), 2233–2240.
3. 3 Kennedy, J, Hill, MD, Ryckborst, KJ, et al. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled trial. Lancet Neurol 6 (2007), 961–969.
4. 4 Wong, KS, Chen, C, Fu, J, et al. Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial. Lancet Neurol 9 (2010), 489–497.
5. 5 Wang, Y, Wang, Y, Zhao, X, et al., for the CHANCE Investigators. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 369 (2013), 11–19.
6. 6 Rothwell, PM, Algra, A, Chen, Z, Diener, HC, Norrving, B, Mehta, Z, Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials. Lancet 388 (2016), 365–375.
7. 7 Wallentin, L, Becker, RC, Budaj, A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361 (2009), 1045–1057.
8. 8 Bonaca, MP, Bhatt, DL, Cohen, M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 372 (2015), 1791–1800.
9. 9 Johnston, SC, Amarenco, P, Albers, GW, et al. Ticagrelor versus aspirin in acute ischemic stroke or transient ischemic attack. N Engl J Med 375 (2016), 35–43.
10. 10 Amarenco, P, Bogousslavsky, J, Caplan, LR, Donnan, GA, Wolf, ME, Hennerici, MG, The ASCOD phenotyping of ischemic stroke (updated ASCO phenotyping). Cerebrovasc Dis 36 (2013), 1–5.
11. 11 Johnston, SC, Amarenco, P, Albers, GW, et al. Acute Stroke or Transient Ischemic Attack Treated with Aspirin or Ticagrelor and Patient Outcomes (SOCRATES) trial: rationale and design. Int J Stroke 10 (2015), 1304–1308.
12. 12 Amarenco, P, Lavallee, PC, Labreuche, J, et al. One-year risk of stroke after transient ischemic attack or minor ischemic stroke. N Engl J Med 374 (2016), 1533–1542.
13. 13 Lovett, JK, Coull, A, Rothwell, PM, for the Oxford Vascular Study. Early risk of recurrent stroke by aetiological subtype: implications for stroke prevention. Neurology 62 (2004), 569–574.
14. 14 Purroy, F, Montaner, J, Molina, CA, Delgado, P, Ribo, M, Alvarez-Sabin, J, Patterns and predictors of early risk of recurrence after transient ischemic attack with respect to etiologic subtypes. Stroke 38 (2007), 3225–3229.
15. 15 Liu, L, Wong, KS, Leng, X, et al. Dual antiplatelet therapy in stroke and ICAS. Subgroup analysis of CHANCE. Neurology 85 (2015), 1154–1162.
16. 16 Sirimarco, G, Lavallée, PC, Labreuche, J, et al. Overlap of diseases underlying ischemic stroke—the ASCOD phenotyping. Stroke 44 (2013), 2427–2433.
17. 17 Amarenco, P, Underlying pathology of stroke of unknown cause (cryptogenic stroke). Cerebrovasc Dis 27:suppl 1 (2009), 97–103.
18. 18 Amarenco, P, Bogousslavsky, J, Caplan, LR, Donnan, GA, Hennerici, MG, Classification of stroke subtypes. Cerebrovasc Dis 27 (2009), 493–501.
19. 19 Saver, JL, Cryptogenic stroke. N Engl J Med 374 (2016), 2065–2074.
20. 20 Hart, RG, Diener, HC, Coutts, SB, et al. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol 13 (2014), 429–438.
21. 21 Chimowitz, MI, Lynn, MJ, Howlett-Smith, H, et al., for the Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 352 (2005), 1305–1316.
22. 22 Benavente, OR, Hart, RG, McClure, LA, Szychowski, JM, Coffey, CS, Pearce, LA, Effect of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med 367 (2012), 817–825.
23. 23 Amarenco, P, Bogousslavsky, J, Callahan, A 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355 (2006), 549–559.
24. 24 Sillesen, H, Amarenco, P, Hennerici, MG, et al. Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 39 (2008), 3297–3302.
25. 25 Diener, HC, Bogousslavsky, J, Brass, LM, et al., for the MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomized, double-blind, placebo-controlled trial. Lancet 364 (2004), 331–337.